Skip to main content
Search
Search
Advanced Search
Skip main navigation
Open access
Industry Update
7 January 2026

Access in all areas? A round-up of developments in market access and health technology assessment: part 12

Authors: Sreeram V Ramagopalan [email protected] and Annie Jullien PannelayAuthor Info & Affiliations
Volume 15, Number 2
https://doi.org/10.57264/cer-2025-0208
PDFFormats

Abstract

In this update we cover the impacts of the US Most Favored Nation pricing policy and research evaluating drug availability and affordability in China as a result of the National Reimbursement Drug List negotiation policy.

Formats available

You can view the full content in the following formats:

View PDFView Full Text

References

1.
Ramagopalan SV, Pannelay AJ. Access in all areas? A round up of developments in market access and health technology assessment: part 9. J. Comp. Eff. Res. 14(10), e250120 (2025).
PubMed
Google Scholar
2.
Ramagopalan SV, Pannelay AJ. Access in all areas? A round-up of developments in market access and health technology assessment: part 10. J. Comp. Eff. Res. 14(11), e250138 (2025).
PubMed
Google Scholar
3.
The White House Fact Sheet: President Donald J. Trump announces first deal to bring most-favored-nation pricing to American patients. The White House (2025). Available from: https://www.whitehouse.gov/fact-sheets/2025/09/fact-sheet-president-donald-j-trump-announces-first-deal-to-bring-most-favored-nation-pricing-to-american-patients/
Google Scholar
4.
The White House Fact Sheet: President Donald J. Trump announces second deal to bring Most-Favored-Nation pricing to American patients. The White House (2025). Available from: https://www.whitehouse.gov/fact-sheets/2025/10/fact-sheet-president-donald-j-trump-announces-second-deal-to-bring-most-favored-nation-pricing-to-american-patients/
Google Scholar
5.
The White House Fact Sheet: President Donald J. Trump announces actions to lower costs and expand access to in vitro fertilization (IVF) and high-quality fertility care. The White House (2025). Available from: https://www.whitehouse.gov/fact-sheets/2025/10/fact-sheet-president-donald-j-trump-announces-actions-to-lower-costs-and-expand-access-to-in-vitro-fertilization-ivf-and-high-quality-fertility-care/
Google Scholar
6.
Bowie K. Mounjaro: UK price set to rise by up to 170% after Trump complaint-will patients have to pay? Brit. Med. J. 390, r1776 (2025).
PubMed
Google Scholar
7.
Bristol Myers Squibb plans to launch Cobenfy (xanomeline and trospium chloride) in the UK at a list price equal to the US launch price. Available from: https://www.bms.com/gb/media/press-release-listing/bristol-myers-squibb-plans-to-launch-cobenfy-in-the-uk-at-a-list-price-equal-to-the-us-launch-price.html
Google Scholar
8.
Ramagopalan SV, Thaker H, Walker M, Narasimhan O. How much do ex-US revenues make a difference for pharmaceutical investment returns? J. Comp. Eff. Res. 14(10), e250121 (2025).
PubMed
Google Scholar
9.
NHS could pay 25% more for medicines under plan to end row with drugmakers and Trump. Guardian Available from: https://www.theguardian.com/business/2025/oct/08/nhs-could-pay-25-more-for-medicines-under-plan-to-end-row-with-drugmakers-and-trump
Google Scholar
10.
Qiu Y, Lyu L, Yi H et al. Impact of China's National Drug Price Negotiation Policy on availability, affordability, and regional equity of negotiated drugs: a multidimensional nationwide analysis, 2018 to 2021. Value Health S1098-3015(25)05652-9 (2025).
PubMed
Google Scholar
11.
Hu Q, Kuai L, Xu D, Lyu L. Impact of six rounds of national drug price negotiation on availability, cost, use, and prices of targeted drugs in China. BMC Health Serv. Res. 25(1), 1421 (2025).
PubMed
Google Scholar
|